Ajanta Pharma Shares Soar 5% on Biocon Semaglutide Deal for Key Markets

• Ajanta Pharma shares jumped 5% after an in-licensing agreement with Biocon Ltd. for the drug Semaglutide.
• Biocon will supply Semaglutide to Ajanta Pharma for exclusive marketing in 23 countries and semi-exclusive in 3 across Africa, Central Asia, and the Middle East.
• Semaglutide, a GLP-1 receptor agonist, improves glycemic control in adults and is a globally accepted blockbuster therapy.
• Ajanta Pharma plans to commercialize the drug in late 2026 or early 2027, following regulatory approvals, after the product patent expires in March 2026.
• MD Yogesh Agarwal expressed excitement about partnering with Biocon to bring this important therapy to Ajanta's strong markets.

Why It Matters: Ajanta Pharma's strategic partnership with Biocon for Semaglutide boosts shares and market reach.